BRAF and melanoma: These findings were confirmed in vivo using four vemurafenib-resistant A375 melanoma clones with elevated p-MEK levels (harboring BRAF amplification, NRASQ61K, or increased TGF-β signaling), which were sensitive to treatment with vorinostat, belinostat, and panobinostat.